Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab.
- Conditions
- Severe Eosinophilic Asthma
- Registration Number
- NCT03833141
- Lead Sponsor
- AstraZeneca
- Brief Summary
This study will generate patient reported outcomes (PROs) associated with the use of benralizumab as treatment for severe eosinophilic asthma.
- Detailed Description
Benralizumab was launched in 2018 following regulatory approval in Canada and is now widely available for Canadian patients with severe eosinophilic asthma.
This study is an observational cohort study of patient reported outcomes (PROs) within real-world settings for participants who are prescribed benralizumab for treatment of uncontrolled severe eosinophilic asthma. Patients will be recruited in select clinics across Canada.
Survey data for each participant in the study will be obtained at the following time-points:
* Baseline (Week 0)
* Short-term follow up: 1-, 2-, 4-, and 8-weeks after baseline
* Long-term follow-up: 24- and 56-weeks after baseline
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 170
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of at least 0.5 units in ACQ-6 after initiation of benralizumab Up to week 56 (from 1st dose of benralizumab) ACQ-6 is able to identify the adequacy of asthma control in individual patients.
Data will be presented as the proportion of patients achieving a change of at least 0.5 units following initiation of therapy.
- Secondary Outcome Measures
Name Time Method Number of exacerbations Up to week 56 (from first dose of benralizumab) The start of an exacerbation is defined as the start-date of systemic corticosteroids or start-date of a temporary increase in a stable oral corticosteroid background dose, or start-date of a hospital admission, whichever occurs earlier.
Data will be presented as an annualized exacerbation rate.EuroQol 5 Dimension, 5 Level (EQ-5D-5L) Up to week 56 (from first dose of benralizumab) The EQ-5D-5L consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS).
The measurement of the EQ-5D-5L health states, defined by the EQ-5D-5L descriptive system, may be converted into a single index value. The index values, presented in country specific value sets, are a major feature of the EQ-5D instrument, facilitating the calculation of quality-adjusted life years (QALYs) that are used to inform economic evaluations of health care interventions.
Index values are presented on a continuum between 0 and 1, with values approaching 1 indicating increasing quality of life (utility).
Data will be presented as mean score as well as a change from baseline score with a measure of dispersion.Asthma Quality of Life Questionnaire, Symptoms (AQLQ(S)+12) Up to week 56 (from first dose of benralizumab) The AQLQ(S)+12 is a questionnaire that measures the health-related quality of life experienced by asthma patients.
The questionnaire comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli).
Patients are asked to recall their experiences during the previous 2 weeks and to score each of the questions on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment). The overall score is calculated as the mean response to all questions, and is presented as a score from 1 to 7, with lower overall scores indicating increasing impairement.
The 4 individual domain scores (symptoms, activity limitations, emotional function, and environmental stimuli) are the means of the responses to the questions in each of the domains.
Individual AQLQ(s)+12 Total or domain score changes of ≥0.5 are considered clinically meaningful.
Data will be presented as a mean score and change from baseline with a measure of dispersion.Change in concomitant medications Up to week 56 (from first dose of benralizumab) Change in concomitant medications (i.e. oral corticosteroid usage) will be measured.
Number of participants with Serious Adverse Events and hospitalizations Up to week 56 (from first dose of benralizumab) Assessment of safety and tolerability through measuring the overall change in number of serious adverse events and hospitalizations.
Data will be presented as the proportion of patients experiencing serious adverse events and hospitalizations.Health care resource utilization Up to week 56 (from first dose of benralizumab) Health Care Resource Utilization (HCRU) will be measured through the overall change in the number of hospitalization visits, visits to the emergency department, and presenteeism/absenteeism from school/work.
Patient Global Impression of Severity (PGI-S) Up to week 56 (from first dose of benralizumab) PGI-S is a 1-item questionnaire designed to assess patient's impression of disease severity. The PGI-S item asks the participant to best describe how their asthma symptoms are now ("Check the one number that best describes how your asthma symptoms are now") on a 4-point scale scored as: "normal" (1), "mild" (2), "moderate" (3), or "severe" (4) .
Data will be presented as a mean score with a change from baseline calculation including a measure of dispersion.Patient Global Impression of Change (PGIC) Up to week 56 (from first dose of benralizumab) The self-reported measure Patient Global Impression of Change (PGIC) reflects a patient's belief about the efficacy of treatment.
PGIC is a 7 point scale depicting a patient's rating of overall improvement.
Patients rate their change as "very much improved," "much improved," "minimally improved," "no change," "minimally worse," "much worse," or "very much worse."
Data will be presented as a mean score with a change from baseline calculation including a measure of dispersion.Treatment Satisfaction Questionnaire for Medication (TSQM-9) Up to week 56 (from first dose of benralizumab) The TSQM-9 treatment satisfaction questionnaire is a measure of Effectiveness, Side effects, Convenience, and Global Satisfaction. The scores range from 0 to 100 with higher scores indicating greater satisfaction.
Data will be presented as a mean score with a change from baseline calculation including a measure of dispersion.
Trial Locations
- Locations (1)
Research Site
🇨🇦Saskatoon, Saskatchewan, Canada